Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer
Xin Li, Lajos Gera, Shumin Zhang, Yanhua Chen, Lei Lou, Lauren Marie Wilson, Zhong‐Ru Xie, Giuseppe A. Sautto, Degang Liu, Alira Danaher, Kenza Mamouni, Yang Yang, Yuhong Du, Haian Fu, Ömer Küçük, Adeboye O. Osunkoya, Jia Zhou, Daqing Wu
Abstract
These results indicate that pharmacological inhibition of EED-EZH2 interaction is a novel strategy for the treatment of chemoresistant PCa. LG1980 and its analogues have the potential to be integrated into standard of care to improve clinical outcomes in PCa patients.
Topics & Concepts
Cancer researchDocetaxelEZH2Prostate cancerIn vivoChemistryPharmacologyBiologyCancerMedicineEpigeneticsInternal medicineBiochemistryGeneBiotechnologyEpigenetics and DNA MethylationRenal and related cancersProstate Cancer Treatment and Research